Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Intuitive Surgical, Inc. stock analysis ISRG overview
Very Bullish +85

Intuitive Surgical Earnings Call Signals Robust Growth

📈 Intuitive Surgical reported Q1 revenue of $2.77 billion, representing a 23% year-over-year increase driven by broad demand for robotic surgery systems.

💰 Recurring revenue reached $2.4 billion, accounting for 86% of total sales and reinforcing the company's high-visibility business model.

🚀 Total procedures climbed 17% year over year to 890,000, with Ion procedures surging 39% and da Vinci procedures rising 16%.

📉 International expansion is a key driver, with procedures outside the U.S. advancing 20% while U.S. volumes grew 15%.

🤖 Company installed 431 da Vinci systems in the quarter, including significant upgrades to da Vinci 5 platforms and increased trade-ins.

🔥 Utilization of newer da Vinci 5 systems is approximately 11% higher than the older Xi platform, boosting per-procedure revenue.

💵 Instruments and accessories revenue grew 23% to $1.7 billion, while I&A revenue per procedure increased to roughly $1,880.

📊 Non-GAAP operating margin reached 39%, and non-GAAP net income jumped to $901 million, outpacing revenue growth in earnings per share.

🌱 Single-Port procedures surged 68% year over year, supported by strong U.S. utilization of the SP system for various surgical needs.

⚕️ Mayo Clinic study data on Ion platform showed a diagnostic yield of 79% and significant increase in early-stage lung cancer diagnoses.

🇨🇳 China remains underperforming due to pricing policies and lack of reimbursement clarity, with no expected improvement until 2027.

🇯🇵 Japan procedure growth trailed historical norms following fewer system placements and potential financial constraints at public hospitals.

⚖️ U.S. da Vinci bariatric procedures declined about 10% due to the increased use of GLP-1 drugs for obesity management.

💻 The company disclosed a cyber incident leading to unauthorized access to some data, though operations remained unaffected.

⚠️ Management warned that tariffs and material costs will weigh on margins in the coming quarters, impacting future profitability growth.

🏦 Quarter-end cash and investments decreased to $8.0 billion due to share repurchases, strategic acquisitions, and capital spending.

👀 Executives remain cautious about potential healthcare policy shifts affecting patient behavior and procedure volumes in the future.

Bullish Signals
  • Intuitive Surgical reported total revenue of $2.77 billion, representing a 23% year-over-year increase or 22% in constant currency.
  • Recurring revenue grew 23% to $2.4 billion and now accounts for 86% of total sales, reinforcing the company's high-visibility business model.
  • Total procedures climbed 17% year over year, with da Vinci procedures rising 16% to 847,000 and Ion procedures jumping 39% to 43,000.
  • The company placed 431 da Vinci systems in the quarter, including 232 da Vinci 5 systems, indicating strong platform adoption and upgrades.
  • Non-GAAP net income climbed to $901 million versus $662 million, while non-GAAP EPS rose to $2.50 from $1.81, showing earnings growth outpacing revenue.
  • Single-Port procedures surged 68% year over year, with U.S. SP system utilization up 22%, highlighting a fast-growing niche within the portfolio.
  • Ion procedure growth reached 39% as hospitals adopt the platform for lung procedures, supported by emerging clinical data showing a diagnostic yield of 79% and malignancy sensitivity of 85%.
  • Non-GAAP operating margin reached 39% with gross margin improving to 67.8%, demonstrating expanding profitability from scale benefits and pricing leverage.
  • Management disclosed that operations and products were not disrupted during the cyber incident, portraying the event as contained despite customer data notifications.
Risk Factors
  • China remains a significant weakness with procedure growth lagging the corporate average due to low tender activity, restrictive pricing policies, and intensifying domestic competition.
  • The company expects no clarity on provincial charge codes and reimbursement in China until 2027, which implies it will likely remain a drag relative to other regions for several years.
  • Japan's procedure growth trailed historical norms following fewer system placements in 2025, pointing to a thinner near-term capital pipeline despite new reimbursement policies taking effect in 2026.
  • U.S. da Vinci bariatric procedures declined about 10% due to increased use of GLP‑1 drugs for obesity management, presenting a structural challenge for this volume segment.
  • A cyber incident occurred in the quarter leading to unauthorized access to customer and employee data, adding a layer of non-financial risk that investors will monitor despite containment efforts.
  • Higher costs from freight, semiconductor memory, oil-related materials, and tariffs are set to weigh on margins later in the year, with updated guidance assuming about a 100-basis-point gross margin impact from tariffs alone.
  • Management remains cautious about potential health-care premium subsidies expiring and how resulting policy shifts could negatively influence patient behavior and procedure volumes over time.
Full Analysis
Intuitive Surgical reported its Q1 earnings with a notably upbeat tone, driven by strong revenue growth of 23% year over year to $2.77 billion. Recurring revenue increased 23% to $2.4 billion, now representing 86% of total sales, which underscores the company's annuity-like business model favored by investors. Total procedures rose 17% to a combined figure where da Vinci procedures reached 847,000 and Ion procedures surged 39% to 43,000. International markets contributed significantly to this volume growth, with procedures outside the U.S. advancing 20% compared to a 15% increase in the domestic market. The company placed 431 da Vinci systems in the quarter, up 17%, and saw a notable shift toward newer platforms like the da Vinci 5, which now accounts for a significant portion of placements including 232 units. This upgrade trend is evident with 119 trade-ins reported versus 67 last year, indicating active adoption of new technology over simple unit expansion. Revenue from instruments and accessories grew 23% to $1.7 billion, while I&A revenue per procedure rose to roughly $1,880. Non-GAAP operating margins reached 39%, with net income climbing to $901 million and non-GAAP EPS increasing to $2.50, demonstrating that earnings growth is outpacing top-line revenue. Despite the robust performance, management highlighted specific headwinds. China remains a weak spot where procedure growth lagged due to tender activity issues and pricing policies, with provincial reimbursement clarity not expected until 2027. Japan also saw slower growth following fewer system placements in 2025, though new reimbursement policies are set for 2026. Additionally, U.S. bariatric procedures declined about 10% linked to increased GLP-1 drug usage, and the company disclosed a cyber incident involving unauthorized access to some data that triggered remediation efforts but did not disrupt operations. Looking ahead, Intuitive warned of potential margin pressure from higher freight, semiconductor memory, oil-related material costs, and tariffs, with guidance assuming roughly a 100-basis-point gross margin impact from tariffs alone. Cash and investments fell to $8.0 billion due to $1.1 billion in share repurchases and capital spending, though the company is investing strategically in European markets through an acquisition of a distributor in Italy, Spain, and Portugal. Executives cautioned that policy shifts regarding health-care premium subsidies could influence patient behavior and volumes over time, even though no material impact was seen in the current quarter.